Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSL ( (AU:CSL) ) has provided an update.
CSL Limited has provided an updated notification to the ASX on the progress of its on-market share buy-back program for its ordinary fully paid shares. The company reported that it had repurchased a total of 4,399,313 shares prior to the latest trading day, with an additional 66,584 shares bought back on the previous day.
The latest filing, dated March 17, 2026, forms part of CSL’s regular daily reporting on the execution of the buy-back first announced in August 2025. Ongoing repurchases signal continued capital management activity, which may support earnings per share and reflects management’s confidence in the company’s valuation and long-term prospects.
The most recent analyst rating on (AU:CSL) stock is a Hold with a A$155.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company listed on the ASX, focused on developing and manufacturing biopharmaceutical products. The group is best known for vaccines, plasma-derived therapies and specialty medicines that serve patients with rare and serious diseases, providing critical treatments to healthcare systems worldwide.
YTD Price Performance: -17.26%
Average Trading Volume: 1,174,556
Technical Sentiment Signal: Sell
Current Market Cap: A$68.44B
For an in-depth examination of CSL stock, go to TipRanks’ Overview page.